NL-OMON21708已完成不适用
BIO-SPAN: BIOsimilar switch, Study on Persistence and role of Attribution and Nocebo
Sint Maartenskliniek Nijmegen0 个研究点目标入组 500 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 500
研究概览
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Switched from Enbrel to Benepali in daily clinical practice in the Sint Maartenskliniek
- •- Older than 18 years of age
排除标准
- 未提供
研究者
相似试验
已完成
4 期
SIMILAR Trial: Santeon InflixMab biosimILAr Research A randomized, controlled, double blind, phase 4 noninferiority trial to assess efficacy of Infliximab-biosimilar (Inflectra) compared to Infliximab-innovator (Remicade) in patients with inflammatory bowel disease in remissioInflammatory Bowel disease: ulcerative colitis and Crohn's disease1001794310003816NL-OMON43635Santeon182
进行中（未招募）
1 期
Efficacy and safety of Infliximab-biosimilar (Inflectra) compared to Infliximab-innovator (Remicade) in patients with inflammatory bowel disease in remission: the SIMILAR Trial”ulcerative colitis and Crohn’s diseaseMedDRA version: 19.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersMedDRA version: 19.0Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2015-001954-14-NLSanteon
已完成
不适用
The effect of switching treatment from innovator infliximab to infliximab biosimilar on efficacy, safety and immunogenicity in patients with rheumatoid arthritis, spondyloarthritis or psoriatic arthritis in daily clinical careBiosimilar, Infliximab, Inflectra, RemsimaNL-OMON24401Participating hospitals are:Sint Maartenskliniek NijmegenMaartenskliniek WoerdenRadboud University Medical Centre NijmegenRijnstate Arnhem200
已完成
3 期
MabionCD20 Compared to MabThera in Lymphoma PatientsDiffuse Large B-Cell LymphomaNCT02617485Mabion SA143
尚未招募
不适用
ongitudinal study of biological surrogate markers in primary progressive Multiple Sclersosis.10012303MSNL-OMON31170Vrije Universiteit Medisch Centrum20